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Abstract 
One of the major hurdles in intravenous regenerative cell therapy is the low homing efficiency to the 
area where these cells are needed. To increase cell homing toward areas of myocardial damage, we 
developed a bispecific tandem single-chain antibody (Tand-scFvSca-1+GPIIb/IIIa) that binds with high affinity to 
activated platelets via the activated glycoprotein (GP)IIb/IIIa receptor, and to a subset of peripheral 
blood mononuclear cells (PBMC) which express the stem cell antigen-1 (Sca-1) receptor.  
Methods: The Tand-scFvSca-1+GPIIb/IIIa was engineered, characterized and tested in a mouse model of 
ischemia-reperfusion (IR) injury applying left coronary artery occlusion for 60 min. Fluorescence cell 
tracking, cell infiltration studies, echocardiographic and histological analyses were performed. 
Results: Treatment of mice undergoing myocardial infarction with targeted-PBMCs led to successful 
cell delivery to the ischemic-reperfused myocardium, followed by a significant decrease in infiltration of 
inflammatory cells. Homing of targeted-PBMCs as shown by fluorescence cell tracking ultimately 
decreased fibrosis, increased capillary density, and restored cardiac function 4 weeks after 
ischemia-reperfusion injury.  
Conclusion: Tand-scFvSca-1+GPIIb/IIIa is a promising candidate to enhance therapeutic cell delivery in order 
to promote myocardial regeneration and thereby preventing heart failure. 
Key words: cell delivery, single-chain antibody, targeting, myocardial infarction, PBMC, regenerative cell 
therapy, cell tracking. 
Introduction 
Acute myocardial infarction (AMI) remains a 
leading cause of mortality and morbidity and a major 
economic burden worldwide [1]. Successful medical 
and interventional treatments mitigate the initial 
cardiac damage during an AMI, but the extent of this 
effect strongly depends on time from onset of 
symptoms to initial treatment. In addition, 
reperfusion causes further damage to the infarcted 
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myocardial tissue. Therefore, there is an unmet need 
for novel therapies to minimize subsequent cardiac 
remodeling and preserve cardiac function.  
Several cell-based therapies, in particular 
various stem and progenitor cell studies in preclinical 
animal models, have undergone intensive 
investigation and yielded great potential to improve 
tissue regeneration, enhance angiogenesis, and restore 
cardiac function after ischemia-reperfusion (IR) injury 
[2-5]. However, cell-based therapy trials for patients 
with AMI have shown disparate outcomes. Some 
trials showed improved left ventricular ejection 
fraction (LVEF) [6-8], but most studies did not find a 
significant benefit after cell therapy [9-11]. Overall, 
current cell therapy fails to deliver the initially 
anticipated clinical benefits.  
Besides poor survival, low proliferation rates, 
insufficient engraftment, and incomplete 
differentiation of the transplanted cells, low cell 
homing efficacy to the infarcted myocardium has 
been one of the major limitations of cell therapy after 
AMI [12]. Previous studies indicated a low homing 
efficacy of only around 2% after intravenous cell 
infusion and around 5% after intracoronary 
transplantation. Instead, the majority of cells homed 
to the lung, liver, and spleen [13-15]. Despite the 
advantages of simplicity, cost-effectiveness, and the 
non-invasive nature of intravenous cell therapy, its 
main drawback is still poor cell retention in the 
ischemia-injured heart [16, 17]. Therefore, targeted 
cell therapy could be a promising tool to enhance cell 
delivery to the infarcted myocardium. 
Crucial for targeted cell therapy is a highly 
specific target epitope to deliver cells to the specific 
area of myocardial injury. Activated platelets play a 
major role after transient myocardial ischemia, as they 
accumulate in the heart directly after reperfusion, and 
this strongly correlates with the size of the ischemic 
and necrotic areas [18-20]. Hence, activated platelets 
represent an ideal target for redirecting cells with 
regenerative potential into the ischemic heart. In 
particular, a single-chain antibody (scFv) targeted 
against active conformation of the major platelet 
integrin glycoprotein (GP)IIb/IIIa (αIIb/βIIIa; 
CD41/CD61) represents a unique targeting epitope 
[21, 22]. Specificity, sensitivity and suitability of the 
scFvGPIIb/IIIa as a targeting tool have been previously 
demonstrated [23-26], as well as specific accumulation 
within the ischemic myocardium [20, 27].  
With the aim of increasing delivery of 
therapeutic cells to sites of cardiac damage and thus 
minimizing cardiac remodeling and restoring cardiac 
function after AMI, we developed a bispecific tandem 
single-chain antibody (Tand-scFv) that binds to 
activated platelets via the GPIIb/IIIa receptor, and to 
a subset of peripheral blood mononuclear cells 
(PBMCs) which express the stem cell antigen-1 (Sca-1) 
receptor. This bispecific Tand-scFvSca-1+GPIIb/IIIa was 
evaluated in functional in vitro assays and an in vivo 
mouse model of myocardial ischemia and 
reperfusion, demonstrating preservation of 
ventricular function and thus corroborating a new 
therapeutic approach for patients with AMI. 
Results 
Construction, expression, and purification of 
the bispecific Tand-scFvSca-1+GPIIb/IIIa and 
Tand-scFvSca-1+Mutant 
We designed and constructed two tandem scFvs, 
the bispecific Tand-scFvSca-1+GPIIb/IIIa and a 
corresponding control antibody, Tand-scFvSca-1+Mutant. 
Both tandem scFv fragments contain an 
N-terminus-located binding immunoglobulin protein 
(BiP) signal for secreting the antibody, followed by the 
scFv directed against Sca-1 to selectively home 
Sca-1–expressing PBMCs to the ischemic myocardium 
and a flexible linker sequence. At the C-terminus of 
the Sca-1 fragment is a linker peptide, followed by 
either of the targeting scFvs, directed against the 
active conformation of GPIIb/IIIa, or the control 
mutant version of this scFv (Figures 1A, B). Both 
proteins consist of a V5/6x-His tag at the C-terminus 
for purification and detection purposes. The designed 
constructs were cloned into the pMT expression 
vector in a tandem format, encoding proteins with a 
molecular weight of approximately 61 kDa. Purified 
diabodies were immunoblotted under reducing 
conditions using a monoclonal anti-His-HRP 
antibody, and the Western Blot showed a band at the 
predicted size of 61 kDa (Figure 1C). 
Binding of both tandem scFvs to activated 
GPIIb/IIIa and Sca-1 
Following the production of 
Tand-scFvSca-1+GPIIb/IIIa and Tand-scFvSca-1+Mutant, 
binding specificity was examined using flow 
cytometry and immunofluorescence staining. One 
binding site of both tandem scFvs is directed against 
Sca-1. Flow cytometry showed high binding affinity 
to Sca-1–expressing mouse PBMC for the 
Tand-scFvSca-1+GPIIb/IIIa as well as the corresponding 
control antibody Tand-scFvSca-1+Mutant (Figure 2A). The 
binding to Sca-1 was further confirmed by 
immunofluorescence staining of a novel generated 
Sca-1–expressing human embryonic kidney (HEK) 
cell line. Immunofluorescence staining of 
Sca-1–expressing HEK cells showed binding by both 
tandem scFvs as well as the commercial Sca-1 control 
antibody (green fluorescence), and confirmed that the 
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scFvSca-1 is functional and binds specifically to Sca-1 
(Figure 2B).  
The second binding site, scFvGPIIb/IIIa, is directed 
against the active conformation of GPIIb/IIIa on the 
platelet surface. Flow cytometry displayed binding of 
the Tand-scFvSca-1+GPIIb/IIIa to activated human 
platelets, while Tand-scFvSca-1+Mutant did not bind to 
activated platelets. Successful platelet activation was 
confirmed using an anti-human PAC-1 antibody 
(Figure 2C). The Tand-scFvSca-1+GPIIb/IIIa preserved this 
activation specificity also on mouse platelets (data not 
shown). In addition, immunofluorescence staining 
was performed to visualize binding of 
Tand-scFvSca-1+GPIIb/IIIa to a monolayer of chinese 
hamster ovary (CHO) cells expressing activated 
GPIIb/IIIa. The control antibody Tand-scFvSca-1+Mutant 
did not bind to CHO cells expressing activated 
GPIIb/IIIa. As a negative control, neither 
Tand-scFvSca-1+GPIIb/IIIa nor Tand-scFvSca-1+Mutant 
showed significant staining of CHO cells expressing 
the resting, non-activated GPIIb/IIIa, and therefore 
confirmed specific binding of Tand-scFvSca-1+GPIIb/IIIa to 
activated GPIIb/IIIa (Figure 2D). 
Bifunctional testing of Tand-scFvSca-1+GPIIb/IIIa 
and Tand-scFvSca-1+Mutant using static and 
dynamic adhesion assays 
To examine the bifunctional character of 
Tand-scFvSca-1+GPIIb/IIIa, static and dynamic adhesion 
assays were performed using Sca-1–expressing HEK 
cells and a monolayer of activated platelets. Static 
adhesion assays showed that pre-incubation with 
Tand-scFvSca-1+GPIIb/IIIa significantly increased the 
adhesion of Sca-1–expressing HEK cells to activated 
platelets compared to pre-incubation with 
Tand-scFvSca-1+Mutant (197 ± 41 vs. 44 ± 33 cells/field of 
view (fov), **p<0.01) or PBS (11 ± 10 cells/fov, 
***p<0.001). Control experiments provided evidence 
that the increase in adhesion was due to binding of 
Tand-scFvSca-1+GPIIb/IIIa to Sca-1 on HEK cells and 
activated GPIIb/IIIa on platelets, since adhesion of 
neither native HEK cells nor control 
Tand-scFvSca-1+Mutant significantly increased adhesion 
to the monolayer of activated platelets (Figure 3A). 
Besides these static adherence conditions, 
adhesion assays under physiological flow conditions 
were performed. Both native and Sca-1–expressing 
HEK cells were perfused over activated platelets 
pre-incubated with one of Tand-scFvSca-1+GPIIb/IIIa, 
Tand-scFvSca-1+Mutant, or PBS. Pre-incubation with 
Tand-scFvSca-1+GPIIb/IIIa showed a significant increase in 
firm adhesion of Sca-1–expressing HEK cells to 
activated platelets compared to pre-incubation with 
Tand-scFvSca-1+Mutant (557 ± 132 vs. 18 ± 14 cells/fov, 
***p<0.001) or PBS (10 ± 7 cells/fov, ***p<0.001). As in 
the static adhesion assays, neither 
Tand-scFvSca-1+GPIIb/IIIa nor Tand-scFvSca-1+Mutant 
increased adhesion of native HEK cells (Figure 3B). 
In summary, these data demonstrate that the 
novel bispecific antibody Tand-scFvSca-1+GPIIb/IIIa can 
direct Sca-1–expressing cells to activated GPIIb/IIIa 
on platelets by specifically interacting with the Sca-1 
antigen and activated GPIIb/IIIa. 
 
 
 
Figure 1. Design and production of the tandem single-chain antibody (Tand-scFv)Sca-1+GPIIb/IIIa and the control Tand-scFvSca-1+Mutant. A) Plasmids of 
Tand-scFvs. Both proteins contain an N-terminal-located binding immunoglobulin protein (BiP) signal, followed by the single-chain antibody (scFv) against Sca-1 and 
a flexible linker sequence. The C-terminus of each protein is formed by a V5/His tag. Between the linker and the V5/His tag is the functional antibody, a scFv targeted 
against activated GPIIb/IIIa, and for the control antibody a mutant version of the scFv. B) Schematic illustration of Tand-scFvs. C) Purified Tand-scFvs, 
Tand-scFvSca-1+GPIIb/IIIa, and Tand-scFvSca-1+Mutant were immunoblotted under reducing conditions using an anti-His-HRP antibody and show a band at approximately 61 
kDa (indicated by the arrow), which is the elxpected molecular weight.  
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Figure 2. In vitro functionality of Tand-scFvSca-1+GPIIb/IIIa and Tand-scFvSca-1+Mutant. A) Representative histograms show strong binding of a commercial Sca-1 
antibody (green), Tand-scFvSca-1+Mutant (blue), and Tand-scFvSca-1+GPIIb/IIIa (red) to PBMCs. B) Representative immunofluorescence images of Sca-1–expressing HEK cells 
showing binding by both constructs as well as by the commercial Sca-1 control antibody (green fluorescence, magnification: 400x, scale bar: 20 µm, n=3). C) 
Representative histograms show high affinity binding of a PAC-1 antibody (green), Tand-scFvSca-1+GPIIb/IIIa (red), but not Tand-scFvSca-1+Mutant (blue) to activated GPIIb/IIIa 
on human platelets. D) Representative immunofluorescence images of activated and non-activated GPIIb/IIIa–expressing CHO cells show specific binding of 
Tand-scFvSca-1+GPIIb/IIIa to activated GPIIb/IIIa but not to non-activated GPIIb/IIIa. Tand-scFvSca-1+Mutant binds to neither activated nor non-activated GPIIb/IIIa–expressing 
CHO cells (green fluorescence, magnification: 200x, scale bar: 50 µm, n=3).  
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Figure 3. In vitro bifunctionality of Tand-scFvSca-1+GPIIb/IIIa and Tand-scFvSca-1+Mutant. Tand-scFvSca-1+GPIIb/IIIa specifically increases adhesion of Sca-1–expressing 
HEK cells to a monolayer of ADP activated human platelets under A) static and B) physiological flow conditions (fov = field of view, n=3). Representative images 
show adhering Sca-1–expressing HEK cells (magnification: 400x (A) and 200x (B), scale bar: 50 µm (A) and 100 µm (B)). Data are represented as mean ± SD. 
 
Characterization and accumulation of 
Tand-scFvSca-1+GPIIb/IIIa-targeted-PBMCs within 
the infarcted myocardium 
Having confirmed that Tand-scFvSca-1+GPIIb/IIIa 
specifically binds to Sca-1 and GPIIb/IIIa and 
furthermore directs Sca-1–expressing cells to 
activated platelets in vitro, we hypothesized that 
Tand-scFvSca-1+GPIIb/IIIa preserves these homing 
properties in vivo and that directing Sca-1–expressing 
cells to activated platelets may have beneficial effects 
after myocardial infarction and reperfusion. This 
hypothesis was tested in a mouse model of cardiac IR 
injury. Mice underwent left coronary artery occlusion 
(CAO) for 1 h followed by reperfusion. Immediately 
after reperfusion, animals were injected with either 
PBS, PBMCs, PBMCs pre-incubated with 
Tand-scFvSca-1+GPIIb/IIIa, or the control antibody 
Tand-scFvSca-1+Mutant, respectively.  
First, Tand-scFvSca-1+GPIIb/IIIa targeted PBMCs 
(targeted-PBMCs) were characterized using flow 
cytometry and it was demonstrated that 55.0 ± 4.1% of 
the PBMCs were Sca-1+. The major subsets of the 
targeted and administered Sca-1+-PBMCs were 
B2-cells (60%), CD4+ T-cells (24.9%), 
Ly6Clow-monocytes (5%), CD8+ T-cells (4.8%), and 
B1-cells (3.3%; Figure 4A, Supplemental Figures S1 + 
S2).  
Next, we wanted to determine whether 
targeted-PBMCs show enhanced delivery to the 
infarcted myocardium. Therefore, mice after IR injury 
were treated with Red CMTPX cell tracker PBMCs 
pre-incubated with Tand-scFvSca-1+GPIIb/IIIa or the 
control antibody. Hearts and blood were imaged 
using an IVIS Lumina XRMS scanner 3 h and 24 h 
after cell injection. IVIS scans showed a significant 
accumulation of targeted-PBMCs in the myocardium 
3 h after IR injury compared to the 
non-targeted-PBMCs and the healthy control heart 
(Figure 4B). No relevant fluorescence signal was 
detected 24 h post IR injury. A scan of whole blood 
displayed that both groups, targeted-PBMCs and 
non-targeted-PBMCs, received comparable amounts 
of PBMCs (Figure 4C). Furthermore, there was no 
significant change in radiance levels in the lung, 
spleen, liver, or bone throughout all groups observed. 
To identify the fate of targeted-PBMCs, infarcted 
cardiac sections were microscopically analyzed 3 h 
after IR injury. Targeted cells (stained with Red 
CMTPX cell tracker dye) could be found mainly in the 
microvasculature while a few cells had migrated into 
the infarcted myocardial tissue (Figure 4D). 
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Figure 4. Enhanced delivery of targeted-PBMCs within infarcted myocardium after IR injury. A) Relative proportion of Sca-1+ PBMC subpopulations 
administered to infarcted mice. B) Representative IVIS image and quantitative analysis show a significant accumulation of targeted-PBMCs within the infarcted 
myocardium compared to non-targeted-PBMCs. C) Representative IVIS image and quantitative analysis of blood samples display comparable amounts of PBMCs 
throughout both treatment groups. Data are represented as mean ± SD, n=3. D) PBMCs were stained with Red CMTPX cell tracker dye and representative images 
of targ-PBMC within the ischemic cardiac sections are shown (magnification: 600x, scale bar: 20 µm, BF: bright field).  
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Figure 5. Treatment with PBMCs pre-incubated with Tand-scFvSca-1+GPIIb/IIIa preserves cardiac systolic function, reduces infarct size, and 
increases neovascularization in a mouse model of IR injury. A) Treatment with targeted-PBMCs shows a significant increase in ejection fraction from week 
1 to week 4 after IR injury (significance between targ-PBMC and non-targ-PBMC in each time category). B) Four weeks post-MI, administration of targeted-PBMCs 
restored ejection fraction compared to administration of non-targeted-PBMCs, PBMCs, PBS, ScFvSca-1+GPIIb/IIIa or ScFvSca-1+Mutant. C) Cardiac sections were stained 
using Masson’s Trichrome. Collagen was stained blue and muscle was counterstained (red). Quantitative analysis of fibrosis within the left ventricle (LV) is shown. 
Administration of targeted-PBMCs caused a significant decrease in fibrosis (scale bar 1 mm, magnification 12.5x). D) Cardiac sections were stained using a CD31 
antibody. Blood vessels were stained brown and cell nuclei were counterstained with hematoxylin (blue). Quantitative analysis of capillary density in a certain tissue 
area (capillaries/mm2) is shown. Treatment with targeted-PBMCs significantly increased neovascularization within the infarcted tissue compared to with 
non-targeted-PBMCs, PBMCs, and PBS (scale bar: 25 μm, magnification: 200x). Data are represented as mean ± SD, n=6-11.  
 
Targeted-PBMCs ameliorate cardiac 
remodeling after IR injury 
Treatment with Tand-scFvSca-1+GPIIb/IIIa-targeted--
PBMCs resulted in continuous improvement in 
cardiac left ventricular (LV) function as demonstrated 
by echocardiography 1, 2, and 4 weeks after IR injury 
(week 1: 53.2 ± 11.1% ejection fraction (EF), week 2: 
61.2 ± 6.5% EF, week 4: 68.4 ± 8.8% EF; Figure 5A). 
After 4 weeks, the improvement achieved was 
significant in the targeted-PBMC group (68.4 ± 8.8% 
EF) relative to the five control groups 
(non-targeted-PBMC: 51.1 ± 10.2% EF, PBMC: 46.2 ± 
4.2% EF, PBS: 50.3 ± 14.0% EF, ScFvSca-1+GPIIb/IIIa: 50.0 ± 
12.8% EF or ScFvSca-1+Mutant: 46.4 ± 11.5% EF *p<0.05, 
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***p<0.001, and ****p<0.0001; Figure 5B). Four weeks 
after IR injury, fibrotic areas in mice treated with 
targeted-PBMCs, as assessed by Masson’s trichrome 
staining, were significantly reduced in comparison to 
mice treated with PBS, PBMCs, or 
non-targeted-PBMCs (Figure 5C). Furthermore, 
angiogenesis was analyzed by immunohistochemistry 
using a CD31 antibody. The average capillary density 
in the infarct zone was significantly enhanced in mice 
treated with targeted-PBMCs compared with all 
control groups (929 ± 148 vs. 544 ± 103 
(non-targeted-PBMCs), 403 ± 61 (PBMCs), and 376 ± 
29 (PBS) capillaries per square millimeter, 
****p<0.0001; Figure 5D). 
Taken together, platelet-targeted cell therapy 
using Tand-scFvSca-1+GPIIb/IIIa-targeted-PBMCs 
preserves cardiac function, decreases fibrosis, and 
enhances neovascularization 28 days after IR injury. 
To investigate the underlying cellular mechanisms of 
this impressive functional improvement, changes in 
secondary cell type infiltration were analyzed 3 days 
after IR injury. 
Tand-scFvSca-1+GPIIb/IIIa-targeted-PBMCs reduce 
inflammatory response after IR injury 
Alterations in secondary cell type infiltration due 
to treatment with Tand-scFvSca-1+GPIIb/IIIa-targeted--
PBMCs were assessed by flow cytometric analysis 3 
days after IR injury (Figure 6A). Mice treated with 
targeted-PBMCs demonstrated an approximately 50% 
 
Figure 6. Changes in leukocytes and leukocyte subpopulations in heart tissue three days after IR injury. A) Mice were euthanized and the hearts 
digested and stained for flow cytometric analysis of different cell populations using the depicted gating strategy. B–E) Bar graphs show quantitative analyses of B) 
infiltrated leukocytes, C) neutrophils, D) monocytes, and E) lymphocytes per mg heart tissue within the infarcted myocardium. Data are represented as mean ± 
SD, n=6–7. 
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reduction in the density of inflammatory cells within 
the infarcted myocardium, as measured by the 
number of total leukocytes per mg heart tissue 
(targeted-PBMCs: 90 ± 29 vs. non-targeted-PBMCs: 
162 ± 51, PBMCs: 190 ± 64, and PBS: 173 ± 41 
leukocytes/mg heart tissue, *p<0.05; Figure 6B). In 
particular, subtype analysis showed that in particular 
the numbers of neutrophils and monocytes were 
decreased after treatment of 
Tand-scFvSca-1+GPIIb/IIIa-targeted PBMCs (Figure 6C–E). 
To support the reduction of inflammation within 
the ischemic myocardium cytokine staining for 
MCP-1, Il-1β, and TNFα was performed 24 h after IR 
injury. As expected, all cytokines were upregulated 
after IR injury as compared to the healthy controls. 
The upregulation was significantly reduced in mice 
treated with targ-PBMC compared to the 
non-targ-PBMC control group (Figure 7).  
Taken together, these data demonstrate that 
treatment of Tand-scFvSca-1+GPIIb/IIIa-targeted PBMCs 
modulated the inflammatory profile by reducing the 
infiltration of inflammatory cells in the myocardium 
after IR injury. 
 
 
Figure 7. Changes in cytokine levels in cardiac tissue 24 hours after IR injury. A) Cardiac section (n=3) were stained for MCP-1, Il-1β, and TNFα. 
Cytokine expression was reduced in the targ-PBMC treated mice compared to non-targ-PBMC mice. Arrows indicate cytokine expressing cells (scale bar: 30 μm, 
magnification: 400x). B) Bar graphs show quantitative analyses of cytokine positive cells per mg heart tissue within the infarct zone. Data are represented as mean ± 
SD, n=3. 
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Discussion 
We generated the unique bivalent recombinant 
single-chain antibody Tand-scFvSca-1+GPIIb/IIIa, which 
specifically binds to activated platelets as well as to 
Sca-1+-PBMCs. Systemic delivery of 
Tand-scFvSca-1+GPIIb/IIIa pre-incubated PBMCs via 
intravenous injection showed enhanced delivery to 
the infarcted myocardium and led to reduced 
infiltration of inflammatory cells, reduced fibrosis, 
enhanced capillary density, and, most importantly, 
restored cardiac LV function after IR injury. 
These findings strongly imply that 
transplantation of platelet-targeted-PBMCs might be 
an effective and novel therapeutic approach for AMI. 
Intravenous cell delivery is the least invasive and 
most convenient route, and leads to a uniform 
distribution of the cells in the infarcted area [16, 17]. 
Despite these advantages, the expected low homing 
efficiency of intravenous cell infusion has instead 
primarily resulted in intramyocardial or 
intracoronary injection being tested in clinical trials 
[13, 28]. However, targeted cell therapy has the 
potential to overcome this limitation. Recent MRI and 
PET/CT studies using the scFvGPIIb/IIIa, which was 
used in our study, showed a highly significant 
accumulation of the targeted antibody to activated 
platelets within the ischemic myocardium after IR 
injury, a uniform distribution throughout the 
ischemic region, as well as occurrence at a 
well-defined time window peaking 2 hours post 
reperfusion [20, 27]. Moreover, the scFvGPIIb/IIIa 
presents an excellent translational tool, as it binds to 
both, human and mouse activated platelets. To 
improve myocardial delivery of systemic cell 
infusion, we developed the antibody 
Tand-scFvSca-1+GPIIb/IIIa, which binds primarily to 
activated platelets and homes toward Sca-1+ cells 
within the ischemic myocardium. Indeed, this specific 
targeting by Tand-scFvSca-1+GPIIb/IIIa leads to significant 
enrichment of the targeted-PBMCs compared to 
non-targeted control PBMCs 3 h after IR injury. 
Therefore, targeted cell therapy is a promising 
approach to increasing cell retention within the 
infarcted myocardium. 
There have been various promising candidates 
that showed safety and potential for cardiac cell 
therapy in preclinical IR injury models, including 
mesenchymal stem cells (MSCs), hematopoietic stem 
cells (HSC), tissue-resident cardiac progenitor cells 
(CPC), cardiac stem cells (CSC), and embryonic stem 
cells (ESC), induced pluripotent stem cells (iPSC), as 
well as bone marrow-derived or peripheral blood 
mononuclear cells (MNCs) [29]. However, results 
showed disparate outcomes in terms of efficacy and 
cardiovascular research still faces the challenge to 
define the best cell type for cardiac cell therapy in 
order to salvage and/or regenerate damaged 
myocardium after AMI [29-31]. While ongoing 
research aims to identify the best source of cells, 
PBMCs were used in this study, as a proof of concept 
to evaluate the potential of the targeting approach.  
In general, the clinical use of PBMCs for 
transplantation is favorable because they can be 
easily, quickly and safely harvested from the 
peripheral blood and even from donors treated with 
antiplatelet agents [7]. In some cases stem cell 
treatment takes too long and is initiated too late to 
have any beneficial effect [32]. In addition, 
regenerative cell therapy in humans requires cell 
numbers in the range of billions. Importantly, this can 
be achieved with PBMCs, as they can be collected 
repeatedly and in sufficient quantities [33]. The 
harvesting of the PBMC population is far less invasive 
than the collection of stem cells, which strongly favors 
the use of PMBCs as cell therapeutics promoting 
cellular repair after AMI. A further major advantage 
of PBMCs as therapeutic cells is their low entrapment 
in the lungs, while various stem cells such as MSCs 
are easily entrapped in the lungs after systemic 
transplantation [14, 16]. This is most likely due to 
PBMCs’ different characteristics compared to stem 
and progenitor cells, such as their smaller cell size, 
only 4–9 µm for mouse PBMCs compared to 20–45 µm 
for mouse MSCs [34]. 
Sca-1 is highly expressed not only on most 
PBMCs, but also on a broad variety of stem and 
progenitor cells, in particular on various types of 
promising regenerative cells including MSC [35], 
tissue-resident CPC [36], CSC [37], several ESCs [38], 
and iPSC [39]. Therefore, our newly developed 
biotechnological approach of delivering Sca-1+ cells 
represents an attractive strategy for various cell-based 
therapies. Sca-1 is a mouse specific antigen, which is 
not expressed in humans. However, the human 
epitope CD34 might be an equivalent antigen to 
choose for translation into patients. CD34 also shows 
a widespread distribution on various types of cells 
such as HPC, HSC, vascular endothelial progenitor 
cells (VPC), MSC, endothelial cells (EC), mast cells, 
interstitial dendritic cells, and fibrocytes and has been 
used for cell directing studies in humans before (e.g. 
CD34-antibody coated coronary artery stents) [40, 41]. 
Using CD34 in humans may allow similar targeted 
cell therapies as shown in our studies with Sca-1 in 
mice. The scFvSca-1 can be easily replaced by a scFv 
against a promising human analogue such as CD34. 
Therefore, our proof of concept study bears 
translational relevance for the treatment of human 
diseases. 
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Our targeted-PBMC approach differs 
substantially from the non-targeted PBMC 
approaches reported so far [7, 42]. Selecting for Sca-1+ 
cells changed the composition of cells delivered for 
cell therapies substantially. For example, the number 
of Ly6Chigh-monocytes decreased from approx. 7% in 
non-targeted-PBMCs to approx. 1% in 
targeted-PBMCs, while Ly6Clow-monocytes increased 
from approx. 2% to 5% in Sca-1+ PBMCs. This shifts 
the monocyte composition toward more 
anti-inflammatory effector cells. 
Most importantly, over 63% of the delivered 
Sca-1+ PBMCs are B cells, mostly B2 cells, and 
therefore their function may be driving the 
paracrine-mediated cardiac-repair mechanisms when 
delivered immediately after AMI. While the roles of 
monocytes and macrophages are well characterized, 
there is little known about the role and underlying 
mechanism of B and T cells after IR injury. These cells 
are currently described as early modulators in 
myocardial healing and remodeling, and show 
disparate outcomes [43]. Both depletion of mature B 
cells using a monoclonal anti-CD20 antibody [44] and 
intramyocardial delivery of BMC-derived B cells [45] 
show therapeutic potential to preserve cardiac 
function. However, the comparison between these 
studies and our study is limited, as they focused on 
the role of bone marrow–derived B cells including T1 
and T2 transitional (immature) B cells in permanent 
ligation models, while our study focuses on 
circulating B cells, mostly B2 cells, in a transient 
ischemia model of cardiac injury. Overall, B cells are 
described as acting by secreting antibodies, as well as 
by paracrine mechanisms such as T-cell activation, 
cytokine and chemokine secretion, monocyte 
mobilization, and antigen presentation [46]. 
Therefore, transplanted targeted-PBMCs are expected 
to act via paracrine effects, rather than 
transdifferentiation and long-term integration into the 
ischemic heart.  
It is well-established that AMI causes an 
inflammatory response characterized by recruitment 
and activation of immune cells of the innate and 
adaptive immune system [47]. Cardiac injury induces 
chemokine and cytokine synthesis in the infarcted 
heart, and this plays a key role in leukocyte 
locomotion and trafficking to the heart [48]. Once in 
the heart, leukocytes contribute to inflammation, 
remodeling, and fibrosis within the myocardium [49]. 
Previous studies clearly demonstrated that depletion 
of neutrophils, as well as moderate reduction of 
monocytes, led to a decrease in IR injury and 
ultimately in reduction of cardiac damage [50, 51]. 
Therefore, a decrease in cytokines and overall 
leukocyte recruitment to the heart following AMI, as 
shown in this study, is indicative of a dampened 
inflammatory response as a potential mechanism for 
the preservation of cardiac function, as seen in mice 
treated with targeted-PBMCs. This study focused on 
the development and characterization of the bispecific 
antibody and the potential of such a targeted antibody 
approach. Further research is required to delineate the 
specific mechanism of the benefits achieved by 
PBMCs. 
Furthermore, the herein developed bispecific 
antibody Tand-scFvSca-1+GPIIb/IIIa holds great promise 
for targeted cell therapy in multiple clinical 
conditions. Imaging of activated platelets using 
scFvGPIIb/IIIa demonstrated the unique potential of this 
tool to accumulate specifically at areas of thrombosis, 
ischemia, or inflammation, making this tool attractive 
for targeted cell delivery to tissues undergoing IR or 
inflammatory reactions [20, 23, 52, 53]. For example, 
Tand-scFvSca-1+GPIIb/IIIa could be a promising 
biotechnological approach to home therapeutic cells 
after ischemic conditions such as stroke or renal 
infarction, as well as inflammation-mediated diseases 
such as rheumatoid arthritis. 
In conclusion, Tand-scFvSca-1+GPIIb/IIIa delivers a 
Sca-1–expressing subset of PBMCs to activated 
platelets within the IR myocardium and thereby 
preserves cardiac function after IR injury. 
Tand-scFvSca-1+GPIIb/IIIa-targeted intravenous delivery 
of PBMCs is therefore a unique and promising 
approach for cell-based therapy, promoting 
myocardial repair after AMI. 
Methods 
Mice 
C57BL/6 and UBC-GFP/B6+/−(Tg) mice were 
acquired from Jackson Laboratories and bred by 
Alfred Medical Research and Education Precinct 
(AMREP) Animal Services in Melbourne, VIC. All 
experimental work was performed in accordance with 
the Australian code for the care and use of animals for 
scientific purposes and approved by the AMREP 
Animal Ethics Committee (E/1402/2013/B). 
Generation, expression, and purification of 
bispecific Tand-scFvSca-1+GPIIb/IIIa and 
Tand-scFvSca-1+Mutant 
Two different scFvs, activated 
GPIIb/IIIa-targeted scFv (scFvGPIIb/IIIa) and 
non-targeted scFv (scFvMutant), were fused with 
scFvSca-1 and cloned into the pMT vector system. A 
detailed description of expression and purification is 
given in the Supplemental Methods. Briefly, both 
scFvSca-1-plasmid constructs were produced using 
CuSO4-induced dimethyldioctadecylammonium 
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bromide (DDAB) transfection in Drosophila 
melanogaster Schneider line-2 (S2) cells (Life 
Technologies). First, cell supernatant was applied to a 
chelating Sepharose fast-flow column to remove the 
non-specific protein and the copper. Both scFvs 
contain a 6xHis tag, which was used for further 
purification with nickel-based metal affinity 
chromatography (Invitrogen). 
Western blotting 
Purified samples were analyzed using SDS gel 
electrophoresis (12% acrylamide, denaturing 
conditions). SDS PAGE was transferred to a 
poly(vinylidene fluoride) membrane (Millipore) for 
immunodetection. The membrane was blocked with 
5% skim milk in PBST and probed with an 
HRP-labeled anti-6xHis tag antibody (Roche). The 
signal was visualized using Super Signal 
Chemiluminescent Substrate (Thermo Scientific). 
PMBC isolation  
UBC-GFP/B6+/−(Tg) donor mice were 
anesthetized and blood was collected into 20 U of 
clexane (Sanofi Aventis) by cardiac puncture. The 
blood was then carefully layered on top of 
Ficoll-Paque (GE Healthcare) and centrifuged at 400 g 
for 30 min, acceleration set at 4 and brakes set at 1. The 
PBMC layer was transferred into Dulbecco’s Modified 
Eagle Medium (DMEM, Life Technologies) and 
centrifuged at 250 g for 10 min. PBMCs were 
resuspended in DMEM and counted. GFP-PBMCs 
were used as donor cells for cell tracking purposes. 
Unfortunately, after using these mice for our study we 
found that the GFP signal in these cells was 
attenuated after isolation and injection. Thus we used 
the CellTrackerTM Red CMTPX Dye for the presented 
cell tracking experiments as described below. 
PBMC characterization 
Isolated PBMCs (n=4) were stained with various 
fluorochrome-labeled anti-mouse antibodies 
(Sca-1-PE or –FITC, NK1.1-PerCP-Cy5.5, CD3-APC, 
TCRγδ-pacific blue, CD11b-APC-Cy7, or 
–PerCP-Cy5.5, CD4-pacific blue, CD8-PerCP, 
CD5-APC, CD19-PE-Cy7, CD45-APC, Ly6C-pacific 
blue, and Ly6G-PerCP-Cy5.5) for 30 min at 4 °C. 
Samples were measured using a FACS Canto II (BD 
Biosciences) and Flowlogic (Inivai technologies) was 
used for FACS analysis. The gating strategy is 
presented in Supplemental Figures S1 + S2. 
Monocytes were gated as CD11b+Ly6G- cells and then 
differentiated between Ly6Chigh and Ly6Clow 
monocytes. CD19+CD5- as a combination of markers 
to identify B2 cells was previously described [54, 55] 
and used in our gating strategy. 
Binding studies of Tand-scFvSca-1+GPIIb/IIIa and 
Tand-scFvSca-1+Mutant by flow cytometry 
Binding capacity of scFvs against Sca-1 receptors 
was performed on freshly isolated mouse PBMCs. 
Study of binding of scFvs against activated GPIIb/IIIa 
was performed on human platelets. Platelets were 
activated using 20 µM ADP. PBMCs and activated 
platelets were incubated with 10 µg/ml 
Tand-scFvSca-1+GPIIb/IIIa and Tand-scFvSca-1+Mutant for 15 
min at room temperature (RT). After washing, cells 
were stained using Penta-His Alexa Fluor 488 
(Qiagen) directed against the 6xHis tag of the 
bispecific scFvs for 15 min in darkness. Binding of 
Tand-scFvSca-1+GPIIb/IIIa and Tand-scFvSca-1+Mutant was 
analyzed using a BD FACS Canto II. 
Generation of Sca-1–expressing HEK cells 
Sca-1–expressing HEK cells were generated by 
stable transfection of HEK cells with pSecTag2A-Sca-1 
DNA. Control HEK cells were transfected with the 
plasmid only, but did not contain Sca-1. Zeocin (Life 
Technologies) was used as the selection reagent at 250 
µg/ml. 
Immunofluorescence staining 
Sca-1–expressing HEK cells and CHO cells 
expressing either activated or non-activated 
GPIIb/IIIa were seeded on coverslides. Cells were 
grown for 2 days, and incubated with 10 µg/ml of 
either Tand-scFvSca-1+GPIIb/IIIa or Tand-scFvSca-1+Mutant, 
followed by a Penta-His Alexa Fluor 488 antibody. 
Cells were visualized with the IX81 Olympus 
microscope (Olympus, Japan) and Cell^P1692 
(ANALysis Image Processing) software. 
Preparation of washed platelets 
Blood was collected from healthy donors into 
citrate and spun at 180 g for 10 min to generate 
platelet rich plasma (PRP). Then, PRP was acidified to 
pH 6.5 using Acid Citrate Dextrose solution B 
(ACD-B) (25 mM citric acid, 45 mM sodium citrate, 80 
mM dextrose). Platelets were pelleted by 
centrifugation at 720 g for 10 min and the pellet was 
reconstituted to original PRP volume with JNL buffer 
pH 6.5 (6 mM dextrose, 130 mM NaCl, 9 mM Na 
bicarbonate, 10 mM Na citrate, 10 mM Tris base, 3 
mM KCl, 2 mM HEPES, 0.81 mM KH2PO4, 0.9 mM 
MgCl2). Platelets were pelleted again by 
centrifugation at 500 g for 10 min, resuspended in 3 
times the original PRP volume using JNL buffer p 7.4 
and were supplemented with CaCl2 (1.8 mM). 
Static adhesion assay 
Washed human platelets were isolated and a 96 
well plate was coated with a monolayer of activated 
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platelets. Briefly, 100 µl of washed platelets were 
added per well and activated using a final 
concentration of 20 µM ADP. After incubation for 20 
min at 37°C platelets formed a monolayer at the 
bottom of the wells. The platelet monolayer was 
rinsed twice with 200 µL of PBS and blocked with 1% 
BSA in Tyrode-HEPES buffer for 30 min at 37°C. In 
the meantime HEK cells and Sca-1 expressing HEK 
cells were harvested and incubated with 10 µg/ml 
Tand-scFvSca-1+GPIIb/IIIa, Tand-scFvSca-1+Mutant or PBS for 
15 min at RT. 1x105 HEK cells per well were incubated 
with the platelet monolayer at 37°C for 10 min. 
Images were acquired using a 400x magnification and 
adhered HEK cells were counted manually.  
Dynamic adhesion assay under flow conditions 
Glass capillaries (0.2 x 2.0 x 100 mm, Vitrocom, 
NJ) were incubated with 100 µl washed human 
platelets for 20 min at 37°C. The platelet monolayer 
was then activated with 20 µM ADP for 15 min at 
37°C, blocked with 1% BSA and incubated with 
10 µg/ml Tand-scFvSca-1+GPIIb/IIIa, Tand-scFvSca-1+Mutant 
or PBS for 30 min at 37°C. Capillaries were connected 
to a programmable syringe pump (PHD 2000, 
Harvard Apparatus) and an inverted microscope was 
used for observation (Olympus IX81). 4x106/ml HEK 
cells were perfused over the platelet monolayer at a 
shear rate of 250 s-1 for 5 min. Three videos along the 
capillary centerline were acquired and adherent cells 
were manually counted offline.  
Myocardial IR injury and echocardiography 
Mice underwent open-chest surgery to induce 
left coronary artery occlusion (CAO) for 1 h, followed 
by reperfusion as described previously [56]. All 
operations were carried out in a blinded manner such 
that the surgeon was blinded to the treatment 
administered. Eight-weeks old, male C57BL/6 mice 
were anesthetized using a combination of ketamine 
HCl (100 mg/kg body weight (wt); Lyppard), 
xylazine HCl (5 mg/kg body wt; Lyppard), and 
atropine (1 mg/kg body wt; Pfizer) via intraperitoneal 
injection. Mice were orally intubated and ventilated 
using a rodent ventilator (Model 687, Harvard 
Apparatus), with a tidal volume of 0.18 ml at 120 
breaths/min. Mice underwent open-chest surgery to 
induce CAO for 1 h, followed by reperfusion. 
Depending on treatment group, immediately after 
reperfusion mice were randomly injected via tail-vein 
with PBS, 1.5x106 GFP-PBMCs, 1.5x106 GFP-PBMCs 
pre-incubated with 140 µg/ml Tand-scFvSca-1+GPIIb/IIIa 
or Tand-scFvSca-1+Mutant, 40 µg per mouse 
Tand-scFvSca-1+GPIIb/IIIa or 40 µg per mouse 
Tand-scFvSca-1+Mutant. 
Following surgery, one group of mice (n=6–7) 
were euthanized after 3 days for analysis of leukocyte 
infiltration. The other group (n=6–11) underwent 
serial echocardiography at 1, 2, and 4 weeks after 
infarction using an iE33 Ultrasound (Philips, 
Netherlands), equipped with a L15-7io transducer. 
Left ventricular ejection fraction was calculated from 
echocardiographic images (short-axis view). 
Echocardiographic imaging and the corresponding 
analyses were performed blinded by two different 
researchers independently from each other. Averages 
of 3 measurements per animal were used. After 28 
days, mice were euthanized for histological analysis.  
PBMC labelling, IVIS imaging and microscopic 
cell tracking 
PBMCs were stained using 25 µM CellTrackerTM 
Red CMTPX Dye (Molecular Probes, excitation (Ex), 
577 nm; emission (Em), 602 nm) for 30 min at 37 °C. 
Cells were then washed twice in DMEM and 
incubated with 140 µg/ml Tand-scFvSca-1+GPIIb/IIIa or 
Tand-scFvSca-1+Mutant for 15 min at RT. Mice underwent 
MI-inducing surgery by CAO. Immediately after 
reperfusion, cells were injected and mice were 
euthanized either 3 h or 24 h after reperfusion. The 
organs were perfused with PBS, collected in 10% 
formalin, and imaged using an IVIS Lumina XRMS 
system (Perkin Elmer). 
After the IVIS scan the hearts were embedded in 
paraffin, cut into 6 µm thick slides and stained with 
4’,6-diamidino-2-phenylindole (DAPI). Samples were 
imaged using the Nikon A1r Plus Confocal 
Microscope, 40x objective. 
Heart digestion and flow cytometry staining 
Three days post-MI, the hearts were flushed with 
Krebs-Henseleit buffer. After weighing and 
mechanical disruption, hearts were digested for 2 h at 
37 °C by an enzyme cocktail of 1.3 U Liberase DL 
Blendzyme (Roche) and 20 U DNase I (Ambion) in 
Tyrode-HEPES buffer. Cells were then passed 
through a cell strainer and stained with an antibody 
cocktail containing CD45-APC, CD11b-APC-Cy7, 
Ly6G-PerCP-Cy5.5, and F4/80-PE, for 30 min at 4 °C. 
Samples were measured using a BD FACS Canto II 
and Flowlogic (Inivai technologies) was used for 
FACS analysis. 
Histology 
Mice were euthanized after 28 days, the hearts 
were harvested and embedded in Tissue-Tek® OCT 
Compound (Sakura, Japan), followed by cutting into 
sections 6 µm thick. Ten defined heart sections for 
each mouse were stained using a Masson’s Trichrome 
Staining Kit (Australian Biostain P/L) according to 
the manufacturer’s protocol. Slides were imaged on 
an Olympus BX50F-3 microscope (Olympus Optical 
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Co., Japan) using 12.5x magnification. Blue-stained 
collagen distribution was measured as the percentage 
area of the total left ventricle using ImageJ v1.48.  
Immunohistochemistry 
Three random cardiac sections for each mouse 
were immunostained using rat anti-mouse CD31 
monoclonal antibody (0.3 µg/ml, BD Pharmingen), 
rabbit anti-mouse MCP-1 antibody (10 µg/ml, 
abcam), rabbit anti-mouse Il-1β antibody (1 µg/ml, 
abcam), rat anti-mouse TNFα antibody (25 µg/ml, BD 
Pharmingen), and a corresponding isotype control 
antibody. The appropriate biotinylated secondary 
antibody (Vector Laboratories) was applied for 30 min 
at RT. Immunostaining of cardiac sections was 
performed with a 
streptavidin–biotin–immunoperoxidase method 
(Vectostatin ABC-Peroxidase and diaminobenzidine; 
Vector Laboratories) per the manufacturer’s protocol. 
Samples were imaged on an Olympus BX50F-3 
microscope using 200x (for CD31) or 400x (for MCP-1, 
Il-1β, TNFα) magnification. The percentages of 
MCP-1-positive, Il-1β-positive, and TNFα-positive 
cells were counted from three random areas in the 
infarcted myocardium of each heart sample (n = 3) or 
the matching heart level for the healthy control and 
were referred to a certain tissue area (mm2). 
Statistical analysis 
Data were statistically analyzed using one- or 
two-way repeated-measures ANOVA. Post hoc, a 
Tukey’s, Sidak’s, or Bonferroni’s multiple 
comparisons test was used. P values of less than 0.05 
were considered statistically significant. All results 
are expressed as mean ± standard deviation (SD). 
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